中邮证券：病理价格精细化政策落地 利好数字化医疗新基建

Core Insights - The National Healthcare Security Administration has officially issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)" which marks a new phase of standardized, regulated, and digital collaborative development in China's pathology medical services [1][2] Group 1: Policy Overview - The guidelines consolidate existing pathology medical service pricing projects into 28 core items, 3 additional charge items, and 2 expansion items, creating a clearer pricing framework [2] - The National Healthcare Security Administration will guide provinces to establish a unified price benchmark, allowing regions to adjust actual execution prices based on this benchmark [2] Group 2: Digital Transformation - The policy emphasizes the application value of digital technology in pathology diagnosis, supporting the promotion of new service models such as digital slides, remote diagnosis, and intelligent analysis [3] - This shift is expected to accelerate the transition of pathology from traditional manual operations to a fully digital process, making pathology data an important "data asset" in medical services [3] Group 3: Beneficiary Companies - Companies like Anbiping, which has automated workstations for specimen processing and supports digital slide applications, are well-positioned to benefit from this policy [4] - Aide Biology focuses on precision medical conditions and has developed an automated reporting and data management system, enhancing its capabilities in pathology services [4] - Zhongyuan Qihua provides comprehensive solutions for major diseases, integrating equipment, reagents, and services to support clinical medical institutions [4] - Maike Biology specializes in providing reagents, equipment, and technical support for pathology diagnosis, aiming for automation and intelligence in laboratory processes [4] - Other companies in the ICL category include Jinyu Medical, Dean Diagnostics, Lanwei Medical, and Aide Kang, which are also expected to benefit from the policy [4]